|
1
|
Bray F, Ferlay J, Soerjomataram I, Siegel
RL, Torre LA and Jemal A: Global cancer statistics 2018: GLOBOCAN
estimates of incidence and mortality worldwide for 36 cancers in
185 countries. CA Cancer J Clin. 68:394–424. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Krook JE, Moertel CG, Gunderson LL, Wieand
HS, Collins RT, Beart RW, Kubista TP, Poon MA, Meyers WC, Mailliard
JA, et al: Effective surgical adjuvant therapy for high-risk rectal
carcinoma. N Engl J Med. 324:709–715. 1991. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Wolmark N, Wieand HS, Hyams DM, Colangelo
L, Dimitrov NV, Romond EH, Wexler M, Prager D, Cruz AB Jr, Gordon
PH, et al: Randomized trial of postoperative adjuvant chemotherapy
with or without radiotherapy for carcinoma of the rectum: National
surgical adjuvant breast and bowel project protocol R-02. J Natl
Cancer Inst. 92:388–396. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Martling A, Holm T, Rutqvist LE, Johansson
H, Moran BJ, Heald RJ and Cedermark B: Impact of a surgical
training programme on rectal cancer outcomes in Stockholm. Br J
Surg. 92:225–229. 2005. View
Article : Google Scholar : PubMed/NCBI
|
|
5
|
van Gijn W, Marijnen CA, Nagtegaal ID,
Kranenbarg EM, Putter H, Wiggers T, Rutten HJ, Påhlman L, Glimelius
B and van de Velde CJ; Dutch Colorectal Cancer Group, :
Preoperative radiotherapy combined with total mesorectal excision
for resectable rectal cancer: 12-Year follow-up of the multicentre,
randomised controlled TME trial. Lancet Oncol. 12:575–582. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Sauer R, Becker H, Hohenberger W, Rödel C,
Wittekind C, Fietkau R, Martus P, Tschmelitsch J, Hager E, Hess CF,
et al: Preoperative versus postoperative chemoradiotherapy for
rectal cancer. N Engl J Med. 351:1731–1740. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Sauer R, Liersch T, Merkel S, Fietkau R,
Hohenberger W, Hess C, Becker H, Raab HR, Villanueva MT, Witzigmann
H, et al: Preoperative versus postoperative chemoradiotherapy for
locally advanced rectal cancer: Results of the German
CAO/ARO/AIO-94 randomized phase III trial after a median follow-up
of 11 years. J Clin Oncol. 30:1926–1933. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Song JH, Jeong JU, Lee JH, Kim SH, Cho HM,
Um JW and Jang HS; Korean Clinical Practice Guideline for Colon and
Rectal Cancer Committee, : Preoperative chemoradiotherapy versus
postoperative chemoradiotherapy for stage II–III resectable rectal
cancer: A meta-analysis of randomized controlled trials. Radiat
Oncol J. 35:198–207. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Li Y, Wang J, Ma X, Tan L, Yan Y, Xue C,
Hui B, Liu R, Ma H and Ren J: A review of neoadjuvant
chemoradiotherapy for locally advanced rectal cancer. Int J Biol
Sci. 12:1022–1031. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Charlton ME, Lin C, Jiang D, Stitzenberg
KB, Halfdanarson TR, Pendergast JF, Chrischilles EA and Wallace RB:
Factors Associated with use of preoperative chemoradiation therapy
for rectal cancer in the cancer care outcomes research and
surveillance consortium. Am J Clin Oncol. 36:572–579. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Barker HE, Paget JT, Khan AA and
Harrington KJ: The tumour microenvironment after radiotherapy:
Mechanisms of resistance and recurrence. Nat Rev Cancer.
15:409–425. 2015. View
Article : Google Scholar : PubMed/NCBI
|
|
12
|
Martin OA, Anderson RL, Narayan K and
MacManus MP: Does the mobilization of circulating tumour cells
during cancer therapy cause metastasis? Nat Rev Clin Oncol.
14:32–44. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Hugen N, van de Velde CJH, de Wilt JHW and
Nagtegaal ID: Metastatic pattern in colorectal cancer is strongly
influenced by histological subtype. Ann Oncol. 25:651–657. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Ding P, Liska D, Tang P, Shia J, Saltz L,
Goodman K, Downey RJ, Nash GM, Temple LK, Paty PB, et al: Pulmonary
recurrence predominates after combined modality therapy for rectal
cancer. An original retrospective study. Ann Surg. 256:111–116.
2012. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Oken MM, Creech RH, Tormey DC, Horton J,
Davis TE, McFadden ET and Carbone PP: Toxicity and response
criteria of the Eastern cooperative oncology group. Am J Clin
Oncol. 5:649–655. 1982. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Hamilton SR, Bosman FT, Boffetta P, Ilyas
M, Morreau H, Nakamura SI, Quirke P, Riboli E and Sobin LH:
Carcinoma of the colon and rectum. WHO Classification of Tumours of
the Digestive System. Bosman FT, Carneiro F, Hruban RH and Theise
ND: IARC. (Lyon). 134–146. 2010.
|
|
17
|
Edge SB, Byrd SR, Compton CC, Fritz AG,
Greene FL and Trotti A: AJCC Cancer Staging Manual. 7th.
Springer-Verlag; New York, NY: pp. 143–164. 2010
|
|
18
|
Hofheinz RD, Wenz F, Post S, Matzdorff A,
Laechelt S, Hartmann JT, Müller L, Link H, Moehler M, Kettner E, et
al: Chemoradiotherapy with capecitabine versus fluorouracil for
locally advanced rectal cancer: A randomised, multicentre,
non-inferiority, phase 3 trial. Lancet Oncol. 13:579–588. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Hong YS, Nam BH, Kim KP, Kim JE, Park SJ,
Park YS, Park JO, Kim SY, Kim TY, Kim JH, et al: Oxaliplatin,
fluorouracil, and leucovorin versus fluorouracil and leucovorin as
adjuvant chemotherapy for locally advanced rectal cancer after
preoperative chemoradiotherapy (ADORE): An open-label, multicentre,
phase 2, randomised controlled trial. Lancet Oncol. 15:1245–1253.
2014. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Austin PC and Stuart EA: Moving towards
best practice when using inverse probability of treatment weighting
(IPTW) using the propensity score to estimate causal treatment
effects in observational studies. Stat Med. 34:3661–3679. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Robins JM, Hernán MA and Brumback B:
Marginal structural models and causal inference in epidemiology.
Epidemiology. 11:550–560. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Brookhart MA, Schneeweiss S, Rothman KJ,
Glynn RJ, Avorn J and Stürmer T: Variable selection for propensity
score models. Am J Epidemiol. 163:1149–1156. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Räsänen M, Carpelan-Holmström M, Mustonen
H, Renkonen-Sinisalo L and Lepistö A: Pattern of rectal cancer
recurrence after curative surgery. Int J Colorectal Dis.
30:775–785. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Segelman J, Akre O, Gustafsson UO, Bottai
M and Martling A: Individualized prediction of risk of metachronous
peritoneal carcinomatosis from colorectal cancer. Colorectal Dis.
16:359–367. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Sakuyama N, Kojima M, Kawano S, Akimoto T,
Saito N, Ito M and Ochiai A: Histological differences between
preoperative chemoradiotherapy and chemotherapy for rectal cancer:
A clinicopathological study. Pathol Int. 66:273–280. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Nagtegaal I, Gaspar C, Marijnen C, van de
Velde C, Fodde R and van Krieken H: Morphological changes in tumour
type after radiotherapy are accompanied by changes in gene
expression profile but not in clinical behaviour. J Pathol.
204:183–192. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Chiang JM, Hsieh PS, Chen JS, Tang R, You
JF and Yeh CY: Rectal cancer level significantly affects rates and
patterns of distant metastases among rectal cancer patients post
curative-intent surgery without neoadjuvant therapy. World J Surg
Oncol. 12:1972014. View Article : Google Scholar : PubMed/NCBI
|
